For Patients

Partnership for Tuberous Sclerosis Complex (TSC)

TSC Alliance Logo

TSC Alliance

The TSC Alliance aims to find a cure while also improving the quality of life for those affected by Tuberous Sclerosis Complex. Their vision is delivered through support of accelerating research, improving access and quality of care, providing support to families, educating, and strengthening the TSC community.

LEARN MORE >

CLINICAL TRIAL

Basimglurant in Children and Adolescents With TSC

PI: Mustafa Sahin MD, PhD  |  Clinical Drug Trial — NCT05059327 >
Patient Advocacy Group Partner: TSC Alliance

CLINICAL TRIAL

Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study (TSC-STEPS)

PI: Mustafa Sahin MD, PhD  |  Clinical Drug Trial — NCT05104983 >
Patient Advocacy Group Partner: TSC Alliance

CLINICAL TRIAL

Topical Sirolimus Ointment for Cutaneous Angiofibromas in Subjects With Tuberous Sclerosis Complex

PI: Mustafa Sahin MD, PhD  |  Clinical Drug Trial — NCT03363763 >
Patient Advocacy Group Partner: TSC Alliance

CLINICAL TRIAL

Preventing Epilepsy Using Vigabatrin In Infants With Tuberous Sclerosis Complex

PI: Mustafa Sahin MD, PhD  |  Clinical Drug Trial — NCT02849457 >
Patient Advocacy Group Partner: TSC Alliance

CLINICAL TRIAL

Adjunctive Ganaxolone Treatment (Part A) in TSC Followed by Long-term Treatment (Part B) (TSC)

PI: Jurriaan Peters, MD, PhD  |  Clinical Drug Trial — NCT04285346 >
Patient Advocacy Group Partner: TSC Alliance

CLINICAL TRIAL

Autism Spectrum Disorder (ASD) and Intellectual Disability (ID) Determinants in Tuberous Sclerosis Complex (TSC)

PI: Mustafa Sahin MD, PhD  |  Natural History Study — NCT02461459 >
Patient Advocacy Group Partner: TSC Alliance